uniQure(QURE) - 2024 Q4 - Annual Results

~ Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential Biologics License Application (BLA) submission ~ ~ Completed patient enrollment in the third cohort of the Phase I/II study of AMT-130 ~ Exhibit 99.1 uniQure Announces 2024 Financial Results and Highlights Recent Company Progress ~ Initiated dosing of the Phase I/II study of AMT-260 in mesial temporal lobe epile ...